Navigation Links
Astrazeneca in Medical News

Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)

ABBOTT PARK, Ill., June 4 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and AstraZeneca announced today that they have entered into an agreement for AstraZeneca to co-promote Abbott's TRILIPIX(R) (fenofibric acid), a medication for use alone or in combination with a statin to treat certain l...

Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia

ABBOTT PARK, Ill. and LONDON, June 4 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and AstraZeneca announced today that the companies have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational compound for the treatment of mixed dyslipidemia...

Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB

SAN DIEGO, May 27 /PRNewswire/ -- Verus Pharmaceuticals, Inc. ("Verus"), a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB ("AstraZeneca") and Tika Lakemedel AB ("Tika") in the Supreme Court of the State of New York, in which it is seeking $1.3 ...

Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca (NYSE: AZN ) for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT ...

Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation

WILMINGTON, Del., April 16 /PRNewswire-FirstCall/ -- On 16 April 2009, the US District Court for the District of New Jersey granted AstraZeneca's request for a temporary restraining order, barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT RE...

FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site

WILMINGTON, Del., April 3 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) is aware that earlier today, the US Food and Drug Administration (FDA) posted to its web site -- and subsequently removed -- briefing documents for the April 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) m...

Video: Astrazeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nation's Number One Killer

2009 Artery Explorer Tour Kicks Off This Month, Urging People Across the Country to Take Action Against Atherosclerosis For immediate release: March 24, 2009 WILMINGTON, Del., March 24 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced the launch of the 2009 US AGAINS...

Washington University in St. Louis and AstraZeneca Announce Alzheimer's Research Collaboration

ST. LOUIS, and WILMINGTON, Del., April 17 /PRNewswire-FirstCall/ -- Washington University School of Medicine in St. Louis and the pharmaceutical company AstraZeneca (NYSE: AZN ) have announced a research collaboration that aims to develop new and improved ways to diagnose and treat Alzheimer'...

Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations

LONDON, March 19 /PRNewswire/ -- Solcara, the market-leading provider of software for the control, management and searching of digital information, has been helping AstraZeneca manage its interactions with the media through the use of Solcara Communications Centre. AstraZeneca, one of the wo...

Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval

ALLEGAN, Mich., Nov. 1 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO ; TASE) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has settled its patent litigation with AstraZeneca (the manufa...
Astrazeneca in Medical Technology

Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination

First Statin and Fibrate Combination in a Single Pill to Target Three Major Lipid Components Moves Forward to Next Phase of Development ABBOTT PARK, Ill. and LONDON, Aug. 31 /PRNewswire-FirstCall/ -- Abbott and AstraZeneca confirmed today they will advance the development of Abbott's next-g...

Jubilant Enters Research Collaboration With AstraZeneca

NOIDA, India, May 5 /PRNewswire/ -- - Research Collaboration to Provide AstraZeneca With New Preclinical Drug Candidates Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collabor...

Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca

Study represents first inclusion of Volcano Revolution(R) 45 MHz IVUS Imaging Catheter in large-scale pharmaceutical plaque progression trial. SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVU...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

... Anderson Cancer Center and pharmaceutical company astrazeneca have reported their work in the Journal of Clini...views at M. D. Anderson. "M.D. Anderson and astrazeneca share a common goal of using leading edge science ...rs in the U.S." In 2005, M. D. Anderson and astrazeneca established a strategic alliance that includes a m...

MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants

... room trips, and inpatient hospital stays for one out of every 334 children. About MedImmune MedImmune, the worldwide biologics business for astrazeneca PLC (LSE: AZN.L, NYSE: AZN ), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

...gation was 5.1 percent in the vandetanib arm. astrazeneca plans to submit a regulatory submission for the us...lf of 2009. ZACTIMA(TM) is a trademark of the astrazeneca group of companies. About lung cancer ...approximately 15%(6). About astrazeneca ...

FDA Advisory Panel Recommends Approval of the SEDASYS(R) System

....com . (C)2009 Ethicon Endo-Surgery SEDASYS(R) is a trademark of Ethicon Endo-Surgery. DIPRIVAN(R) is a registered trademark of the astrazeneca group of companies. CONTACTS: Media: Investor Relations: Kelly Leadem Stan Panasewicz ...

MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants

... room trips, and inpatient hospital stays for one out of every 334 children. About MedImmune MedImmune, the worldwide biologics business for astrazeneca PLC (LSE: AZN.L, NYSE: AZN ), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline...

AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product

...ILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- astrazeneca (NYSE: AZN ) today announced the submission of a...c and/or duodenal ulcers in patients at risk. astrazeneca also submitted a supplemental new drug application...ose ASA may develop upper GI symptoms.(5A,6A) astrazeneca conducted two studies to evaluate the safety and e...

ePharmaSolutions' Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award

...om 107 countries for the top 20 pharmaceutical companies in the world. "To be selected along side such companies as Wyeth, GSK, Merck, Abbott and astrazeneca is truly an honor," said Enrico DePaolis, President & Chief Operating Officer for ePharmaSolutions. "Our teams have been working exceptionally ha...
Astrazeneca in Biological News

CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda

... KGaA Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, astrazeneca Arthur L. Holden, Ph.D., Chairman and Chief Executive Officer, Inter... Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, astrazeneca Pharmaceuticals, Inc. Chetan Lathia, Ph.D., Director, Global Clinica...

La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery

...a Institute for Allergy & Immunology has been licensed by MedImmune, a leading innovation-focused biotechnology company and wholly owned subsidiary of astrazeneca PLC. MedImmune licensed the discovery to explore its use in the development of a potential biologics drug for treating asthma. Under the agreem...

European membrane expertise to focus on new treatments for human diseases

... Industry has also seen the benefit of bringing such expertise together under one umbrella and working with the academics will be pharmaceutical giant astrazeneca and a smaller company, Xention, which specialises in the discovery and development of novel and selective ion channel drugs. The researchers includ...

Further breakthroughs for breast cancer patients

... a combination of tamoxifen and AZD0530 could actually prevent drug resistance occurring in the first place. The Src inhibitor AZD0530 developed by astrazeneca is currently in early clinical trials. If the results seen in the laboratory can be reproduced in the clinic, this approach could offer a substantial ...

Social habits of cells may hold key to fighting diseases

...nt in these projects will allow us to achieve much added value and to develop and show best practice across all of them. Professor Hans Westerhoff, astrazeneca Professor of Systems Biology and Director of the Doctoral Training Centre on Systems Biology at The University of Manchester, said: This is a unique o...

Mouse gene shows new mechanism behind cardiac infarction in man

...udy is published this week on Nature Genetics Online. Researchers at Karolinska Institutet, in collaboration with the Jackson Laboratory in the USA, astrazeneca and a Japanese research group, have scrutinised an area on chromosome 1 that is of demonstrable importance to the development of arteriosclerosis. The...
Astrazeneca in Biological Technology

BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications

BEIJING, March 23 /PRNewswire/ -- BioDuro and AstraZeneca announced today that they have expanded their research collaboration to optimize discovery research for Respiratory and Inflammation indications. BioDuro will provide integrated research services in the areas of discovery chemistry, d...

Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)

ABBOTT PARK, Ill. and WILMINGTON, Del., Aug. 14 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT ) and AstraZeneca (NYSE: AZN ) announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR(R) (rosuvastatin calcium), a medication used along with diet to redu...

Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology

GOTHENBURG, Sweden, June 11 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced a new collaborative agreement with AstraZeneca. Under the agreement Cellectricon will provide AstraZeneca with two of its new groundbreaking high throughput p...

Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation

Companies Also Sign Manufacturing and Distribution Agreement GURGAON, India and PRINCETON, N.J., April 15 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has reached several agreements with Astra...

Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery

LONDON, March 13 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN), focused on the development of a range of novel approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' leading expertise ...

Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development

MANCHESTER, England, February 5 /PRNewswire-FirstCall/ -- Epistem plc (LSE:EHP) announced today that it had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug develop...

Melior Enters Research Collaboration with AstraZeneca

Melior Discovery, Inc. announced today that it has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo theraTRACE indications discovery platform will be used to evaluate the therapeutic activity of selected AstraZeneca compounds. EXTON, Pa. (Bus...

Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca

AstraZeneca's CEO to be Deposed in London on Friday, June 20, 2008 NEW YORK, June 19 /PRNewswire/ -- Weitz & Luxenberg, PC, one of the leading plaintiffs' litigation law firms in America, filed a lawsuit today against pharmaceutical giant AstraZeneca on behalf of a New York City Fire Depart...

WuXi PharmaTech (NYSE: WX) Expands Collaboration With AstraZeneca

SHANGHAI, China, June 10 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has signed a new three-year collaboration ...

Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca

- Expands the Company's Clinical Stage Product Portfolio - ANN ARBOR, Mich., Feb. 6 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced that it is has completed a global licensing agreement to make, develop and commercialize products under AstraZeneca's IP and know-how regar...
Other Tags
(Date:5/22/2015)... 2015 Mountain Point Medical Center, a campus ... ceremony on Friday, May 29, 2015 at 11 a.m., followed ... The new medical center, set to officially open on June ... UT 84043. , “The opening of Mountain Point Medical ... Utah County community,” said Kent Loosle, CEO of Mountain Point ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 ... Health IT solutions, announced today that Bill Lane, ... is the developer of BlueEHS,a first of its ... offers a customizable Electronic Health Records (EHR) with ... interfaces, a telemedicine-enabled comprehensive patient portal, and more. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 sweetFrog Enterprises, LLC. ... in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog store ... chain was listed as #22 on the Inc. 500 list ... have lived and worked in East Texas for 20 years ... Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog locations. ...
Breaking Medicine News(10 mins):Health News:Mountain Point Medical Center, a Campus of Jordan Valley Medical Center, Hosts Ribbon Cutting Ceremony and Community Celebration on Friday, May 29, 2015 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
Other Contents